The FDA has approved a third respiratory syncytial virus vaccine for high-risk adults aged younger than 50 years — a ...

Arexvy will now compete for market share with Pfizer’s Abrysvo and Moderna’s mRESVIA in this expanded, high-risk adult ...

Valneva (NASDAQ:VALN) executives highlighted steady full-year 2025 revenue, tighter cash discipline, and multiple clinical ...

By Nate Raymond, Ahmed Aboulenein and Leah Douglas BOSTON, March 16 (Reuters) - A federal judge on Monday blocked key parts ...

RNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA ...

The ECDC, the infectious diseases watchdog, has asked for scientists to join its new panel on RSV as Europe begins to vaccinate its most vulnerable adults.

A fourth dose of bivalent or monovalent BA.1-adapted BNT162b2 vaccines was safe and elicited robust neutralizing responses in adults aged 18 to 55 years.

Total revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following ...

Six years after early vaccine trials, the legacy of COVID-19 shots reflects science, public debate, and how perceptions ...

After a career spanning two decades at Bear Stearns, Lehman Brothers, and Morgan Stanley, I gained an institutional perspective on dividend stock investing. My tenure at these premier Wall Street ...

Pfizer (PFE) stock is in focus as a mid-stage trial for the company's investigational breast cancer therapy, atirmociclib succeeds. Read more here.

March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in patients with breast cancer. Here are some details: * Pfizer's ...